Skip to main content
. 2014 Jul 1;4:5516. doi: 10.1038/srep05516

Figure 3.

Figure 3

Improvement of respiratory symptoms including dyspnea (modified medical research council, mMRC, A) and lung function (peak expiratory flow, PEF, B) during the treatment of AECOPD (day 0, 4, 7 and 14) and in the subsequent baseline (8 w).